MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss
-$43,604K
Net loss
-$43,320K
Total other
comprehensive loss (gain)
-$284K
Interest and investment
income
$2,791K
Operating loss
-$46,111K
Unrealized loss (gain) on
marketable securities
-$284K
Total operating
expenses
$46,111K
Research and development
$37,617K
General and
administrative
$8,494K
Back
Back
Income Statement
source: myfinsight.com
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)